Barr looks set to complete Pliva acquisition
The Croatian government has said that it is going to sell its 17% stake in Pliva to Barr Pharmaceuticals, which makes it likely that the US drugmaker, which offered 820 kuna ($142) per share, will finally complete the purchase. Last month, Icelandic generic drugs firm Actavis pulled out of the bidding war over the Croatian Pliva group, saying that it will not increase its 795 kunas per share bid (Marketletter September 25). Bruce Downey, Barr's chief executive, has consistently said that his firm is committed to completing the acquisition, which would make it the third-largest generic drugmaker worldwide.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze